Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses hair regrowth results after using finasteride, minoxidil, and dermarolling for four months. Users inquire about dosages and when results were first noticed.

Pyrilutamide is effective for mild hair loss, especially when finasteride isn't an option, but it's less effective than finasteride and requires consistent application. It's best for early-stage hair loss and works well in combination with other treatments like minoxidil.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

A user had 4000 hair grafts in Denmark and started taking 0.5mg finasteride daily, reporting good progress after four months. The procedure cost 55,000 DKK (7,400 euros) and the user is pleased with the results, especially in the temples and crown areas.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.

The user wants to mix 0.2 ml of RU58841 solution with 2 ml of Alfatradiol to use 10 mg of RU58841 daily due to concerns about side effects. They are asking if this combination would be effective for hair loss treatment.

People have reported hair thickening with Pyrilutamide, particularly using a 1% concentration. Some users are curious about the availability of different concentrations like 0.9%.

The conversation discusses whether to resume using RU58841 for hair loss, as the user is already on finasteride but noticing visible scalp. Users suggest continuing RU58841 despite its cost if it boosts confidence, and some mention considering minoxidil or other treatments.

The user saw significant hair regrowth after using rosemary-castor oil, scalp massages, a derma roller, biotin shampoo, minoxidil-finasteride spray, and a PRP injection. They plan to continue this routine.

Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

Reincarnation humorously suggested as a hair restoration method, with exaggerated and satirical discussions on finasteride use. The conversation includes jokes about side effects and the absurdity of extreme measures for hair loss.

The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.

Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.

Finasteride can affect sperm quality, but fertility usually returns after stopping it, as shown by a user who conceived four months after discontinuation. Some users successfully conceive while on finasteride, though some prefer to pause its use to minimize risks.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

PP405 is being discussed as a promising hair loss treatment, potentially effective when combined with minoxidil and pyrilutamide. Some users are skeptical about rapid hair regrowth claims, while others are considering alternatives like GT20029 and pyrilutamide instead of finasteride.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

The post and conversation discuss the effectiveness of pyrilutamide for hair loss, with comparisons to finasteride and RU58841. Users express skepticism due to failed trials and high costs, with some waiting for more data before trying pyrilutamide.

A 25-year-old male has been using finasteride since October 2022 to combat diffuse thinning and hairline recession, experiencing initial shedding but later stabilization. He plans to add oral minoxidil to improve hair density and is open to trying dutasteride if necessary, with minimal side effects reported.

PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

PP405 now has a Wikipedia page, generating more discussion and attention. One user plans to continue using finasteride until PP405 is proven effective and widely available.

The user experienced significant hair regrowth using oral finasteride 1.25mg daily and a Capillus RX laser cap, with no side effects. Improvement was noticed after 9 months, and shedding stopped after the initial 4-5 months.

Using 0.25mg of finasteride daily for 7 months resulted in thicker hair and slowed hair recession without side effects. The user plans to continue this dosage and may add dermarolling or ketoconazole shampoo for maintenance.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.